Pfizer Inc. today announced positive topline progression-free (PFS) survival results from Cohort 3, a separate randomized cohort of the pivotal BREAKWATER trial, evaluating BRAFTOVI® (encorafenib) in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results